Sponsor:
Arog Pharmaceuticals, Inc.
Code:
NCT03258931
Conditions
Newly Diagnosed FLT3 Mutated AML
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Crenolanib
Midostaurin
Cytarabine
Duanorubicin
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Arog Pharmaceuticals, Inc. on 2020-05-22.